Advanced radiation treatment planning and delivery approaches for treatment of lung cancer

Hematology/Oncology Clinics of North America

Volumn 18, Issue 1, 2004, Pages 231-243

  Martel, Mary K ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREATHING; CANCER CONTROL; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; GEOGRAPHY; HUMAN; LUNG CARCINOMA; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; REVIEW; TECHNOLOGY; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 1042298786     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(03)00149-7     Document Type: Review

References (53)

1. Vijayakumar S., Myrianthopoulos L.C., Rosenberg I.et al. Optimization of radical radiotherapy with beam's eye view techniques for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 21:1991;779-788.
2. Hayman J.A., Martel M.K., Ten Haken R.et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol. 19(1):2001;127-136.
3. Rosenzweig K.E., Mychalczak B., Fuks Z.et al. Final report of the 70. 2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer. Cancer J. 6(2):2000;82-87.
4. RTOG 93-11. A phase I/II dose escalation study using three dimensional conformal radiation therapy in patients with inoperable nonsmall cell lung cancer. 1993;. Available at: http://www.rtog.org. Accessed January 6, 2004.
5. Belderbos J.S.A., De Jaeger K., Heemsbergen W.D.et al. First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. Radiother Oncol. 66:2003;119-126.
6. Martel M.K., Ten Haken R.K., Hazuka M.B.et al. Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer. 24(1):1999;31-37.
7. Armstrong J., Raben A., Zelefsky M.et al. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol. 44(1):1997;17-22.
8. Graham M.V., Purdy J.A., Emami B.et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 45(2):1999;323-329.
9. Cox J.D., Azarnia N., Byhardt R.W.et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma - Report of Radiation Therapy Oncology Group 83-11. J Clin Oncol. 8:1990;1543-1555.
10. McShan D.L., Fraass B.A., Lichter A.S. Full integration of the beam's eye view concept into computerized treatment planning. Int J Radiat Oncol Biol Phys. 18(6):1990;1485-1494.
11. Emami B., Lyman J., Brown A.et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 21:1991;109-122.
12. Martel M.K., Ten Haken R.K., Hazuka M.B.et al. Dose volume histogram and 3-D treatment planning evaluation of patients with pneumonitis. Int J Radiat Oncol Biol Phys. 28(3):1994;575-583.
13. Oetzel D., Schraube P., Hensley F.et al. Estimation of pneumonitis risk in three-dimensional treatment planning using dose volume histogram analysis. Int J Radiat Oncol Biol Phys. 33:1995;455.
14. Marks L.B., Munley M., Bentel G.et al. Physical and biological predictors of changes in whole-lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys. 39:1997;563.
15. Hernando M.L., Marks L.B., Bentel G.C.et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol, Biol Phys. 51(3):2001;650-659.
16. Graham M.V., Purdy J.A., Emami B.E.et al. Clinical dose volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 45(2):1999;323-329.
17. Kwa S., Lebesque J., Theuws J.et al. Radiation pneumonitis as a function of mean dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys. 42:1998;1.
18. Seppenwoolde Y., Lebesque J.V., de Jaeger K.et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. Int J Radiat Oncol Biol Phys. 55(3):2003;724-735.
19. Lyman J.T. Complication probability as assessed from dose volume histograms. Radiat Res. 8:1985;13-19.
20. Marks L.B., Munley M.T., Bentel G.C.et al. Physical and biological predictors of changes in whole-lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys. 39(3):1997;563-570.
21. Boersma L.J., Damen E.M., de Boer R.W.et al. A new method to determine dose-effect relations for local lung-function changes using correlated SPECT and CT data. Radiother Oncol. 29(2):1993;110-116.
22. Lind P.A., Marks L.B., Hollis D.et al. Receiver operating characteristic curves to assess predictors of radiation-induced symptomatic lung injury. Int J Radiat Oncol Biol Phys. 54(2):2002;340-347.
23. Seppenwoolde Y., Engelsman M., de Jaeger K.et al. Optimizing radiation treatment plans for lung cancer using lung perfusion information. Radiother Oncol. 63(2):2002;165-177.
24. eff and iso-NTCP in the implementation of dose escalation protocols. Int J Radiat Oncol Biol Phys. 27:1993;689-695.
25. Prescribing, recording and reporting photon beam therapy. Report 50. 1993;ICRU, Bethesda (MD).
26. Senan S., Burgers S., Samson M.J.et al. Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy. Int J Radiat Oncol Biol Phys. 54(4):2002;999-1006.
27. Bowden P., Fisher R., Mac Manus M.et al. Measurement of lung tumor volumes using three-dimensional computer planning software. Int J Radiat Oncol Biol Phys. 53(3):2002;566-573.
28. Senan S., van Sornsen de Koste J., Samson M.et al. Evaluation of a target contouring protocol for 3D conformal radiotherapy in non-small cell lung cancer. Radiother Oncol. 53(3):1999;247-255.
29. Giraud P., Antoine M., Larrouy A.et al. Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys. 48(4):2000;1015-1024.
30. Kiffer J., Berlangieri S., Scott A.et al. The contribution of FDG positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer. 19:1998;167-177.
31. Munley M., Marks L., Scarfone C.et al. Multimodality nuclear medicine imaging in 3-D radiation treatment planning for lung cancer: challenges and prospects. Lung Cancer. 23:1999;105-114.
32. Nestle U., Walter K., Schmidt S.et al. FDG PET for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Rad Onc Biol Phys. 44:1999;593-597.
33. Vanuytsel L.J., Vansteenkiste J.F., Stroobants S.G.et al. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol. 55(3):2000;317-324.
34. Mah K., Caldwell C.B., Ung Y.C.et al. The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys. 52(2):2002;339-350.
35. 18FDG-PET in radiation therapy treatment planning: influence of minimum threshold intensity on tumor volume definition for lung cancer. Int J Radiat Oncol Biol Phys, in press.
36. Ekberg L., Holmberg O., Wittgren L.et al. What margins should be added to the clinical target volume in radiotherapy treatment planning for lung cancer? Radiother Oncol. 48(1):1998;71-77.
37. Stevens C.W., Munden R.F., Forster K.M.et al. Respiratory-driven lung tumor motion is independent of tumor size, tumor location, and pulmonary function. Int J Radiat Oncol Biol Phys. 51(1):2001;62-68.
38. Yamada K., Soejima T., Yoden E.et al. Improvement of three-dimensional treatment planning models of small lung targets using high-speed multi-slice computed tomographic imaging. Int J Radiat Oncol Biol Phys. 54(4):2002;1210- 1216.
39. Lagerwaard F.J., Van Sornsen de Koste J.R., Nijssen-Visser M.R.et al. Multiple "slow" CT scans for incorporating lung tumor mobility in radiotherapy planning. Int J Radiat Oncol Biol Phys. 51(4):2001;932-937.
40. van Sornsen J.R., Lagerwaard F.J., Nijssen-Vissner M.R.J.et al. Tumor location cannot predict the mobility of lung tumors: a 3D analysis of data generated from multiple CT scans. Int J Radiat Oncol Biol Phys. 56(2):2003;348-354.
41. Wong J.W., Sharpe M.B., Jaffray D.A.et al. The use of active breathing control (ABC) to reduce margin for breathing motion. Int J Radiat Oncol Biol Phys. 44(4):1999;911-919.
42. Kubo H.D., Len P.M., Minohara S.et al. Breathing-synchronized radiotherapy program at the University of California Davis Cancer Center. Med Phys. 27(2):2000;346-353.
43. Keall P.J., Kini V.R., Vedam S.S.et al. Motion adaptive x-ray therapy: a feasibility study. Phys Med Biol. 46(1):2001;1-10.
44. Webb S. Intensity modulated radiation therapy. 2001;Institute of Physics Publishing, Philadelphia.
45. Derycke S., De Gersem W.R., Van Duyse B.B.et al. Conformal radiotherapy of stage III non-small cell lung cancer: a class solution involving non-coplanar intensity-modulated beams. Int J Radiat Oncol Biol Phys. 41(4):1998;771-777.
46. van Sornsen de Koste J., Voet P., Dirkx M.et al. An evaluation of two techniques for beam intensity modulation in patients irradiated for stage III non-small cell lung cancer. Lung Cancer. 32(2):2001;145-153.
47. Marnitz S., Stuschke M., Bohsung J.et al. Intraindividual comparison of conventional three-dimensional radiotherapy and intensity modulated radiotherapy in the therapy of locally advanced non-small cell lung cancer a planning study. Strahlenther Onkol. 178(11):2002;651-658.
48. Yu C.X., Jaffray D.A., Wong J.W. The effects of intra-fraction organ motion on the delivery of dynamic intensity modulation. Phys Med Biol. 43(1):1998;91-104.
49. Lax I., Blomgren H., Naslund I.et al. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol (Madr). 33(6):1994;677-683.
50. Blomgren H., Lax I., Naslund I.et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol (Madr). 34(6):1995;861-870.
51. Hof H., Herfarth K.K., Munter M.et al. Stereotactic single-dose radiotherapy of stage I NSCLC. Int J Radiat Oncol Biol Phys. 56(2):2003;335-341.
52. Timmerman R., Papiez L., McGarry R., et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I NSCLC, Chest, in press.
53. Hara R., Itami J., Kondo T.et al. Stereotactic single high dose irradiation of lung tumors under respiratory gating. Radiother Oncol. 63(2):2002;159-163.